Biocon Limited has informed the Exchange about Investor Presentation
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon reported Q1 FY26 total revenue of ₹4,022 Cr, up 15% year-on-year on a like-for-like basis, driven by 18% growth in Biosimilars (₹2,458 Cr) and 11% growth in CRDMO services (₹875 Cr). Core EBITDA stood at ₹1,003 Cr with margins at 25%, while reported net profit was just ₹31 Cr, down sharply from ₹660 Cr in the year-ago quarter due to the absence of a one-time ₹1,057 Cr gain from the BFI divestment in the base quarter. The company successfully raised ₹4,500 Cr via a QIP, the first equity raise since its 2004 IPO, which will be used to increase its stake in Biocon Biologics and reduce debt. Key milestones included US FDA approval for Kirsty (interchangeable Insulin Aspart), launch of Yesafili in Canada, and UK approvals for Denosumab, marking entry into bone health. Biosimilars margins expanded by 300 bps YoY to 24%, while Generics margins came under pressure from new facility ramp-up costs.
Shareholders should note the headline net profit decline is purely a base-effect distortion from last year's one-time divestment gain; underlying biosimilars business is showing strong margin expansion and the QIP strengthens the balance sheet. Short-term stock reaction may be muted due to weak Generics profitability, but the diversified growth across biosimilars approvals, CRDMO demand, and GLP-1 investments signals a positive medium-term setup.